31
Natalizumab, which is currently being marketed by Biogen, is a humanized monoclonal antibody against the cell adhesion molecule ?4-integrin. It is a disease-modifying therapy for RRMS. Around 85% of people with multiple sclerosis are diagnosed with RRMS, Polpharma states.
This important commercial agreement marks a significant milestone in Polpharma Biologic’s ongoing commitment to producing more affordable, high-quality biopharmaceuticals for patients worldwide, said Jerzy Starak, Chairman of Polpharma Biologics. We are delighted to combine expertise with our collaboration partner Sandoz AG to expand patient access to this important treatment…